The Indian Serum Institute is scheduled to apply for emergency approval of the vaccine from Oxford University and the pharmaceutical company AstraZeneca in the next two weeks.
On November 28, the director of the Indian Serum Institute Adar Poonawala confirmed that the institute can produce at least 100 million doses of vaccine a month since the beginning of 2021. He made the statement after a visit to the Prime Minister’s factory. Narendra Modi. The government is expecting 300-400 million injections by July next year, as the country faces a new outbreak.
AstraZeneca says more research is needed on the vaccine after trial confusion. According to the report, scientists at the Jenner Institute, University of Oxford, missed half of the vaccine in the first nose to 500 volunteers. Instead of starting over, they increased the number of people taking the study and injected the correct dose. Those who “mistakenly injected” the first half of the vaccine are still on the program. They get enough injections in the second nose. Thus, the trial unintentionally divided into two regimens: two doses and 1.5 doses. As a result, the vaccine injected with enough doses only achieved 61% protection, while the group that injected 1.5 shots was 90% effective.
AstraZeneca confirmed the results did not affect the regulatory agency’s vaccine approval process. “There is a bit of confusion in communication. This will be clearly explained in the next few days. But it will not impact emergency use approvals in the UK or India. allowed in the next two weeks”, said Mr. Poonawalla.
He affirmed that the timing of approval by the regulator does not affect the distribution work. The institute produces about 50-60 million injections per month. After another month to two, the output will increase to about 100 million doses.
The institute will focus on supplying supplies to India and more than 150 countries in the Covax alliance. This is a program led by the World Health Organization (WHO) to ensure equitable distribution of vaccines to developing countries.
AstraZeneca and Oxford University claim the vaccine is priced lower than its competitors on the market, and is easy to store and distribute because it can be stored and handled at higher temperatures.
Poonawalla urged manufacturers to be cautious about vaccine information so that the public should not be afraid to use them. “In a world where people constantly question vaccines, we, the media, the manufacturers, the government and everyone, should work together to spread the right message,” he said.
Currently, India is one of the largest epidemic regions in the world. As of November 30, the country had recorded more than 9 million cases and at least 137,000 deaths from Covid-19.